Akademik Veri Yönetim Sistemi
Cumhuriyet Tıp Dergisi (Cumhuriyet Medical Journal, CMJ), cilt.43, sa.2, ss.134-143, 2021 (Hakemli Dergi)
Objective: PD-1 (programmed death-1) is an immune checkpoint receptor
that modulates T-cell activity in peripheral tissues via interaction with its
ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed
death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to dampen T
lymphocyte attack. The checkpoint inhibition by tumor cells via the PD-1
pathway suppress the antitumor immune response. The role of PD-1
pathway has been extensively investigated in non-hematologic
malignancies, however, the exact role of this pathway is not established in
hematologic disorders. So, we aimed to demostrate the PD-1 and PD-L2
expresion rate of various lymphoma subtypes, and to evaluate whether PD1 and PD-L2 expresion have impact on prognosis.
Method: For this purpose, pre-treatment lymph node biopsy specimens of
92 patients [25 Hodgkin lymphoma (HL) and 67 non-Hodgkin lymphoma
(NHL)] have been stained with monoclonal
antibody immunstains of PD-1 and PD-L2.
Results: The overall expression rate of PD-1 was 76% and 82.1% in patients
with HL and NHL, respectively. PD-L2 expression rate was weak in both
HL and NHL cases. Since we have evaluated whether there is a correlation
between immunohistochemistry (IHC) results and survival of patients with
HL and NHL, we couldn’t demonstrate a meaningful evidence that these
markers have an impact on prognosis.
Conclusions: We conclude that the role of PD-1 pathway can be
demonstrated by IHC. If IHC markers might be standardized in the future,
especially a cutoff that defines a clinically significant positive and
predictive value, may help identifying patients more likely to benefit from
anti-PD-1 therapies.